Insider trading

Period: 120 months Stock: STAA + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

188 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

188 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

188 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

188 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
188 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
188 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

188 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
1 Jun 2021
Sold, plan not stated
$148.41K 1,014 at 146.36
0.0%
28 May 2021
Sold, plan not stated
$32.09M 217,693 at 147.43
2.3%
27 May 2021
Sold, plan not stated
$6.82M 47,571 at 143.42
0.5%
24 May 2021
Blickensdoerfer Hans-Martin Sr. VP, Comm. Ops, China
Sold, plan not stated
$12.37M 94,855 at 130.42
46.7%
24 May 2021
Francese James E Sr. VP, Comm. Ops., NA, APAC
Sold, plan not stated
$1.89M 14,500 at 130.42
21.6%
21 May 2021
Francese James E Sr. VP, Comm. Ops., NA, APAC
Sold, plan not stated
$1.94M 15,261 at 126.83
22.5%
21 May 2021
Blickensdoerfer Hans-Martin Sr. VP, Comm. Ops, China
Sold, plan not stated
$658.56K 5,145 at 128.00
4.5%
12 May 2021
Hansen Graydon C. Sr. VP, Global Operations
Sold, plan not stated
$612.50K 5,531 at 110.74
38.5%
11 May 2021
Mason Caren L President & CEO
Sold, plan not stated
$5.92M 53,500 at 110.70
45.8%
11 May 2021
Hansen Graydon C. Sr. VP, Global Operations
Sold, plan not stated
$1.24M 11,075 at 111.61
43.5%
10 May 2021
Mason Caren L President & CEO
Sold, plan not stated
$6.41M 53,500 at 119.88
45.8%
10 May 2021
Hayashida Jon K. VP, Global Clinical, Medical
Sold, plan not stated 2×
$1.50M 12,109 at 124.25
59.2%
Sold half or more
10 May 2021
Francese James E Sr. VP, Comm. Ops., NA, APAC
Sold, plan not stated
$1.46M 11,583 at 125.72
18.0%
10 May 2021
Holliday Keith Chief Technology Officer
Sold, plan not stated
$1.12M 8,874 at 125.83
28.1%
26 Apr 2021
Sold, plan not stated
$5.87M 43,383 at 135.30
0.5%
23 Apr 2021
Sold, plan not stated
$7.19M 53,854 at 133.51
0.6%
22 Apr 2021
Sold, plan not stated
$2.69M 20,669 at 130.34
0.2%
22 Mar 2021
Hayashida Jon K. VP, Global Clinical, Medical
Sold, plan not stated
$106.30K 1,103 at 96.37
10.2%
22 Mar 2021
Gesten Samuel J Chief Legal Officer
Sold, plan not stated
$99.45K 1,032 at 96.37
2.4%
22 Mar 2021
Francese James E Sr. VP, Comm. Ops., NA, APAC
Sold, plan not stated
$88.85K 922 at 96.37
1.7%
3 Mar 2021
Mason Caren L President & CEO
Sold, plan not stated
$4.42M 45,000 at 98.32
50.6%
Sold half or more
2 Mar 2021
Mason Caren L President & CEO
Sold, plan not stated
$4.66M 45,000 at 103.53
50.6%
Sold half or more
1 Mar 2021
Mason Caren L President & CEO
Sold, plan not stated
$4.71M 45,000 at 104.76
50.6%
Sold half or more
1 Mar 2021
Hansen Graydon C. Sr. VP, Global Operations
Sold, plan not stated 3×
$3.49M 33,790 at 103.33
70.2%
Sold half or more
1 Mar 2021
SILVERMAN LOU Director
Sold, plan not stated
$2.51M 23,996 at 104.78
91.9%
Sold half or more
1 Mar 2021
Holliday Keith Chief Technology Officer
Sold, plan not stated 2×
$1.99M 18,991 at 104.55
39.5%
1 Mar 2021
Hayashida Jon K. VP, Global Clinical, Medical
Sold, plan not stated
$1.69M 16,000 at 105.43
59.7%
Sold half or more
12 Feb 2021
Sold, plan not stated
$2.76M 22,250 at 124.22
0.2%
11 Feb 2021
Sold, plan not stated
$922.87K 7,412 at 124.51
0.1%
10 Feb 2021
Sold, plan not stated
$972.85K 7,789 at 124.90
0.1%
9 Feb 2021
Sold, plan not stated
$8.08M 65,081 at 124.09
0.7%
8 Feb 2021
Sold, plan not stated
$17.71M 144,838 at 122.28
1.5%
5 Feb 2021
Sold, plan not stated
$5.54M 47,700 at 116.09
0.5%
4 Feb 2021
Sold, plan not stated
$5.41M 48,687 at 111.15
0.5%
3 Feb 2021
Sold, plan not stated
$1.17M 10,585 at 110.44
0.1%
2 Feb 2021
Sold, plan not stated
$175.30K 1,589 at 110.32
0.0%
28 Jan 2021
Sold, plan not stated
$29.44M 278,197 at 105.83
2.7%
27 Jan 2021
Sold, plan not stated
$17.13M 164,686 at 103.99
1.6%
26 Jan 2021
Sold, plan not stated
$35.51M 347,000 at 102.33
3.2%
12 Jan 2021
Sold, plan not stated
$5.36M 60,000 at 89.28
0.6%
23 Nov 2020
Francese James E Sr. VP, Comm. Ops., NA, APAC
Sold, plan not stated
$1.52M 18,959 at 80.13
27.0%
23 Nov 2020
Blickensdoerfer Hans-Martin Sr. VP, Comm. Ops, China
Sold, plan not stated 2×
$396.68K 4,774 at 83.09
4.2%
20 Nov 2020
Blickensdoerfer Hans-Martin Sr. VP, Comm. Ops, China
Sold, plan not stated
$223.16K 2,688 at 83.02
2.4%
19 Nov 2020
Blickensdoerfer Hans-Martin Sr. VP, Comm. Ops, China
Sold, plan not stated
$1.15M 14,007 at 82.03
10.9%
9 Nov 2020
Holliday Keith Chief Technology Officer
Sold, plan not stated
$1.93M 23,714 at 81.56
40.9%
9 Nov 2020
Hayashida Jon K. VP, Global Clinical, Medical
Sold, plan not stated
$1.63M 20,000 at 81.34
64.9%
Sold half or more
15 Sep 2020
Holliday Keith Chief Technology Officer
Sold, plan not stated
$1.94M 36,326 at 53.33
65.3%
Sold half or more
14 Sep 2020
Holliday Keith Chief Technology Officer
Sold, plan not stated 2×
$1.90M 35,689 at 53.32
64.9%
Sold half or more
9 Sep 2020
Moore John C Director · indirect
Sold, plan not stated
$7.15M 137,331 at 52.04
86.5%
Sold half or more
10 Aug 2020
Hayashida Jon K. VP, Global Clinical, Medical
Sold, plan not stated
$2.13M 41,602 at 51.22
79.4%
Sold half or more
Showing 101–150 of 188. ← Newer Page 3 of 4 Older →